全国29823例精神分裂症患者抗精神病药物治疗真实世界有效性
结果显示,氯氮平和长效注射抗精神病药预防复发效果最佳,长效注射剂再住院风险比等效口服剂型低约20%至30%。
要点
- 氯氮平和长效注射抗精神病药预防精神分裂症复发效果最佳。
- 长效注射剂再住院风险比等效口服剂型低约20%至30%。
- 口服氟哌噻吨、喹硫平和口服奋乃静再住院风险最高。
核心结论
- 氯氮平和长效注射抗精神病药物是预防精神分裂症复发效果最好的药物治疗。
- 长效注射剂治疗期间再住院风险比等效口服剂型低约20%至30%。
研究设计与样本
- 前瞻性收集的瑞典全国数据库链接研究,随访期为2006年7月1日至2013年12月31日。
- 主要分析采用个体内分析以消除选择偏倚,次要分析采用传统Cox比例风险多变量回归。
主要发现
- 与未使用抗精神病药物相比,精神科再住院风险最低为每月一次长效注射帕利哌酮(HR 0.51;95%CI 0.41-0.64)、长效注射珠氯噻醇(HR 0.53;95%CI 0.48-0.57)、氯氮平(HR 0.53;95%CI 0.48-0.58)、长效注射奋乃静(HR 0.58;95%CI 0.52-0.65)和长效注射奥氮平(HR 0.58;95%CI 0.44-0.77)。
- 口服氟哌噻吨(HR 0.92;95%CI 0.74-1.14)、喹硫平(HR 0.91;95%CI 0.83-1.00)和口服奋乃静(HR 0.86;95%CI 0.77-0.97)与再住院风险最高相关。
- 长效注射抗精神病药物再住院风险显著低于等效口服剂型(总队列HR 0.78;95%CI 0.72-0.84;新诊断队列HR 0.68;95%CI 0.53-0.86)。
- 与最广泛使用的口服奥氮平相比,氯氮平(HR 0.58;95%CI 0.53-0.63)和所有长效注射抗精神病药物(HR 0.65-0.80)治疗失败率最低。
临床怎么用
- 真实世界证据支持在精神分裂症维持治疗中优先考虑氯氮平和长效注射抗精神病药物以预防复发。
- 对口服剂型依从性不佳或复发风险高的患者,长效注射剂可能比等效口服剂型更有效降低再住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It has remained unclear whether there are clinically meaningful differences between antipsychotic treatments with regard to preventing relapse of schizophrenia, owing to the impossibility of including large unselected patient populations in randomized clinical trials, as well as residual confounding from selection biases in observational studies. OBJECTIVE: To study the comparative real-world effectiveness of antipsychotic treatments for patients with schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: Prospectively gathered nationwide databases were linked to study the risk of rehospitalization and treatment failure from July 1, 2006, to December 31, 2013, among all patients in Sweden with a schizophrenia diagnosis who were 16 to 64 years of age in 2006 (29 823 patients in the total prevalent cohort; 4603 in the incident cohort of newly diagnosed patients). Within-individual analyses were used for primary analyses, in which each individual was used as his or her own control to eliminate selection bias. Traditional Cox proportional hazards multivariate regression was used for secondary analyses. MAIN OUTCOMES AND MEASURES: Risk of rehospitalization and treatment failure (defined as psychiatric rehospitalization, suicide attempt, discontinuation or switch to other medication, or death). RESULTS: There were 29 823 patients (12 822 women and 17 001 men; mean [SD] age, 44.9 [12.0] years). During follow-up, 13 042 of 29 823 patients (43.7%) were rehospitalized, and 20 225 of 28 189 patients (71.7%) experienced treatment failure. The risk of psychiatric rehospitalization was the lowest during monotherapy with once-monthly long-acting injectable paliperidone (hazard ratio [HR], 0.51; 95% CI, 0.41-0.64), long-acting injectable zuclopenthixol (HR, 0.53; 95% CI, 0.48-0.57), clozapine (HR, 0.53; 95% CI, 0.48-0.58), long-acting injectable perphenazine (HR, 0.58; 95% CI, 0.52-0.65), and long-acting injectable olanzapine (HR, 0.58; 95% CI, 0.44-0.77) compared with no use of antipsychotic medication. Oral flupentixol (HR, 0.92; 95% CI, 0.74-1.14), quetiapine (HR, 0.91; 95% CI, 0.83-1.00), and oral perphenazine (HR, 0.86; 95% CI, 0.77-0.97) were associated with the highest risk of rehospitalization. Long-acting injectable antipsychotic medications were associated with substantially lower risk of rehospitalization compared with equivalent oral formulations (HR, 0.78; 95% CI, 0.72-0.84 in the total cohort; HR, 0.68; 95% CI, 0.53-0.86 in the incident cohort). Clozapine (HR, 0.58; 95% CI, 0.53-0.63) and all long-acting injectable antipsychotic medications (HRs 0.65-0.80) were associated with the lowest rates of treatment failure compared with the most widely used medication, oral olanzapine. The results of several sensitivity analyses were consistent with those of the primary analyses. CONCLUSIONS AND RELEVANCE: Clozapine and long-acting injectable antipsychotic medications were the pharmacologic treatments with the highest rates of prevention of relapse in schizophrenia. The risk of rehospitalization is about 20% to 30% lower during long-acting injectable treatments compared with equivalent oral formulations.
引用
- Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. JAMA Psychiatry. 2017. PMID: 28593216. doi:10.1001/jamapsychiatry.2017.1322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。